Flatiron Health and Via Oncology Announce Availability of Via Pathways for Medical Oncology in OncoEMR

March 16, 2016

Flatiron Health and Via Oncology announced today that Via Pathways for breast, colon, rectal, non-small cell and small-cell lung, mesothelioma, prostate, and multiple myeloma cancers are now available fully embedded in Flatiron Health’s OncoEMR® electronic health record (EHR). Via Pathways for additional tumor types will be available throughout 2016.

“Using Via Pathways directly in OncoEMR brings real time evidence-based decision support to our clinicians at the point of care. Additionally, this fully integrated model saves time by avoiding duplicate data entry,” said Frank Senecal, MD, Northwest Medical Specialties. Northwest Medical Specialties was the first practice to go live with Via Pathways embedded in OncoEMR.

As announced in 2015, the Flatiron Health and Via Oncology partnership enables providers using OncoEMR and licensing Via Pathways to seamlessly select evidence-based regimens within their clinical workflow, report on pathways adherence directly within OncoEMR and utilize pathways to participate in value-based reimbursement models. With this product milestone, OncoEMR is now the only cloud-based medical oncology EHR that allows providers to choose their preferred pathways and medical content, including Via Pathways, directly within the EHR at the point of care.

Kathy Lokay, President and CEO, Via Oncology, added, “By leveraging PathBuildR, our dynamic content authoring tool, and Flatiron Health’s industry-leading cloud-based software platform, our mutual customers can stay up to date with the most current Via Pathways.”

“We heard from providers across the country that there was a desire to bring pathways directly into the EHR,” said Robert J. Green, MD, Senior Vice President, Clinical Oncology, Flatiron Health. “As a result, our engineering and clinical teams developed software to fully embed the Via Pathways decision support tool within OncoEMR and help providers improve efficiency and standardize treatment selection across patients and diseases. By utilizing Via Pathways in OncoEMR, providers have a mechanism to demonstrate adherence to evidence-based care and participate in value-based care programs.”

This is part of Flatiron Health’s commitment to continually invest in software solutions for its clients. Coming soon, the company will unveil the new OncoCloud® Suite, a next-generation cloud-based oncology software suite. To learn more about licensing the Via Pathways in OncoEMR today, please visit: www.flatiron.com/viapathways.


NEW YORK, NY, March 15, 2016

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Media Contact: Nina Toor